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Abstract
Background: Proneurotrophins and mature neurotrophins elicit opposite effects via the p75 neurotrophin
receptor (p75NTR) and Trk tyrosine kinase receptors, respectively; however the molecular roles of
proneurotrophins in the CNS are not fully understood.
Results: Based on two rare single nucleotide polymorphisms (SNPs) of the human brain-derived neurotrophic factor
(BDNF) gene, we generated R125M-, R127L- and R125M/R127L-BDNF, which have amino acid substitution(s) near
the cleavage site between the pro- and mature-domain of BDNF. Western blot analyses demonstrated that these
BDNF variants are poorly cleaved and result in the predominant secretion of proBDNF. Using these cleavage-
resistant proBDNF (CR-proBDNF) variants, the molecular and cellular roles of proBDNF on the CNS neurons
were examined. First, CR-proBDNF showed normal intracellular distribution and secretion in cultured
hippocampal neurons, suggesting that inhibition of proBDNF cleavage does not affect intracellular transportation
and secretion of BDNF. Second, we purified recombinant CR-proBDNF and tested its biological effects using
cultured CNS neurons. Treatment with CR-proBDNF elicited apoptosis of cultured cerebellar granule neurons
(CGNs), while treatment with mature BDNF (matBDNF) promoted cell survival. Third, we examined the effects
of CR-proBDNF on neuronal morphology using more than 2-week cultures of basal forebrain cholinergic neurons
(BFCNs) and hippocampal neurons. Interestingly, in marked contrast to the action of matBDNF, which increased
the number of cholinergic fibers and hippocampal dendritic spines, CR-proBDNF dramatically reduced the
number of cholinergic fibers and hippocampal dendritic spines, without affecting the survival of these neurons.
Conclusion: These results suggest that proBDNF has distinct functions in different populations of CNS neurons
and might be responsible for specific physiological cellular processes in the brain.
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The development and functioning of the mammalian
nervous system are regulated by neurotrophins, that are a
family of neurotrophic factors which includes nerve
growth factor (NGF), BDNF, neurotrophin-3 (NT-3), and
NT-4/5 [1]. Like many peptide hormones and growth fac-
tors, neurotrophins are first synthesized as precursors and
are subsequently cleaved either intracellularly by prohor-
mone convertases (PCs) and/or furin, or extracellularly by
plasmin and matrix metalloproteases (MMPs) to form
mature proteins [2]. These proteins elicit their biological
actions by binding to the Trk family of receptor-type tyro-
sine kinases [3]. For decades, proneurotrophins were
thought to be biologically inactive; the dogma was
changed when Lee et al. [4] reported that proNGF prefer-
entially interacted with p75NTR instead of Trk receptors.
This interaction leads to apoptosis of peripheral neurons,
an effect opposite to the pro-survival action of mature
NGF. Since then, proapoptotic effects of proNGF and
proBDNF mediated by p75NTR have been demonstrated in
a number of model systems [4-8]. Therefore, proteolytic
cleavage of proneurotrophins is thought to be an impor-
tant regulatory step for the direction of neurotrophin
function, given the diametrically opposed functions of
proneurotrophins and mature neurotrophins, which are
elicited via the p75NTR and Trk receptors, respectively
[9,10].
The cleavage of proBDNF (125RVRR128↓ HS in Fig. 1A), [2]
is thought to take place either intracellularly by serine pro-
teases such as PC1/3 and/or furin, or extracellularly by
extracellular proteinases such as plasmin activated by tis-
sue plasminogen activator (tPA), and/or MMPs. The
importance of proBDNF cleavage has been reported
recently [11,12]. These two reports suggest that proBDNF
cleavage in the nervous system is regulated in a more spe-
cific manner and depends on the cellular context.
However, little is known about the function of proBDNF
when compared with the numerous reports on the mech-
anisms of mature BDNF (matBDNF) action [10,13]. In
vitro experiments have shown that proBDNF enhances
apoptosis of sympathetic neurons and basal forebrain
neurons [7,8,14]. Application of exogenous proBDNF
facilitates long-term depression (LTD), through an inter-
action with p75NTR [15], suggesting that proBDNF may
exert multiple biological actions in the nervous system.
Another important question is whether proBDNF has a
physiological function [10,13]. The two rare human SNPs
at nucleotides 373 (G/T) and 379 (G/T) (Reference SNP
cluster id: rs1048220 and rs1048221, respectively)
present in the coding region of the human BDNF gene are
located near the cleavage site (Fig. 1A) and theoretically
lead to the substitution of the arginine residues (R) by
methionine (R125M) and leucine (R127L), respectively
(Fig. 1A). Although the precise validation for these SNPs
has not been fully determined, cDNA analysis on R125M
suggests that one out of 92 persons from Utah State car-
ried M-type BDNF gene http://www.ncbi.nlm.nih.gov/
sites/entrez. Thus, these polymorphisms may affect the
cellular mechanisms and biological functions of BDNF in
human brain.
In the present study, taking advantage of the cleavage
resistance of these BDNF variants (CR-proBDNF), various
cultured CNS neurons including hippocampal neurons,
CGNs, and BFCNs were treated with recombinant CR-
proBDNF protein to address the molecular functions of
proBDNF on CNS neurons. Our studies suggested that
CR-proBDNF showed normal intracellular distribution
and secretion in cultured hippocampal neurons and that
CR-proBDNF exerts distinct functions in cerebellar gran-
ule neurons (CGNs), basal forebrain cholinergic neurons
(BFCNs) and hippocampal neurons.
Results
A bioinformatic analysis predicted SNPs-dependent 
changes in the secondary structure of proBDNF
In an initial attempt to study the effects of the rare SNPs
(Fig. 1A), we analyzed the secondary structure of the
human BDNF protein corresponding to the region con-
taining SNPs using a bioinformatic tool, Predictor of Nat-
ural Disordered Regions algorithm (PONDR) [16]. The
tool, which predicts the disordered regions in the pro-
teins, identified regions corresponding to amino acids
(aa) 25–103 and aa 120–140 to be disordered (Fig. 1B,
PONDR score > 0.5). Consistent with the X-ray structure
analysis [17], mature domain of BDNF (residue 129–247)
was predicted to be thermally stable. However, when the
human SNP mutations (Fig. 1A, R125M and R127L) were
introduced, the PONDR score, and hence the degree of
disorder, decreased markedly (Fig. 1B, aa 120–140, M, L
and ML) suggesting that the region encompassing the pro-
tease cleavage site may undergo disordered-to-ordered
transition when associated with other proteins, such as
the proteases [16]. This result raises the possibility that the
amino acid substitutions caused by SNPs may affect the
molecular interaction of proBDNF with proteases and
consequently interfere with the cleavage of proBDNF
itself.
R125M-, R127L-, and R125M/R127L-BDNF SNP variants 
are poorly cleaved in hippocampal neurons
We next introduced wild-type BDNF (RR) or the BDNF
variants: R125M (M), R127L (L), or R125M/R127L (ML),
which were tagged with a Myc epitope at the C-terminus
[Additional file 1A], into cultured hippocampal neurons
using Sindbis virus infection [18]. To normalize for the
efficiency of gene transfer, we used a bicistronic vectorPage 2 of 19
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BDNF polymorphic substitutions inhibit the conversion of proBDNF to matBDNF and lead to predominant secretion of proBDNF in CNS ne ronsFigure 1
BDNF polymorphic substitutions inhibit the conversion of proBDNF to matBDNF and lead to predominant 
secretion of proBDNF in CNS neurons. (A) Schematic of human BDNF protein. Amino acid substitutions near the cleav-
age site in rare SNP variants are represented by single-letter symbols. The amino acid substitutions caused by the SNPs are 
depicted by white symbols. (B) Bioinformatic prediction of changes in the secondary structure of proBDNF SNPs variants using 
PONDR. M, L and ML depict the amino acid substitution of R125M, R127L and R125M/R127L, respectively. The disordered 
regions (PONDR score > 0.5) of wild-type BDNF (aa 25–103 and 120–140) is highlighted by bold lines. (C) Inhibition of the 
intracellular cleavage of SNP variants in cultured hippocampal neurons. The cultures were infected with Sindbis viruses 
expressing wild-type (RR), R125M (M), R127L (L), and R125M/R127L (ML) constructs for 12 h and 3 days later processed for 
Western blot analysis using anti-BDNF (IB: BDNF) and anti-Myc antibodies (IB: Myc). Doublet bands of 29- and 32-kDa were 
detected with the monoclonal anti-proBDNF antibody (IB: proBDNF), whereas an additional band of 14-kDa (matBDNF) was 
detected using an antibody against the mature domain (IB: BDNF). The levels of bicistronically expressed GFP, which corre-
lated with the viral infection levels, were similar in all cultures. Note that proBDNF bands were predominant in the lysates of 
cells expressing the M, L, and ML constructs, while matBDNF expression was residual. In C and F, 1 ng recombinant matBDNF 
and proBDNF (R125M/R127L-BDNF) were used as positive controls. (D) The ratio of proBDNF to matBDNF was quantified 
by densitometric analysis on BDNF, and proBDNF bands. **P < 0.01 (Student's t-test) when compared with matBDNF (mat-
BDNFRR + proBDNFRR = 100% as control). n = 3 independent experiments. (E) The entire amount of BDNF was quantified by 
densitometric analysis on matBDNF, proBDNF, and GFP bands. *P < 0.05 (t-test) when compared with RR (100% as control). 
n = 3 independent experiments. (F) Secretion of poorly cleaved proBDNF. Cultured cerebral cortical neurons were incubated 
with Sindbis viruses for 12 h and maintained in serum-containing medium for 3 days. Supernatants were collected and immuno-
precipitated using anti-Myc antibody-conjugated agarose beads, followed by Western blot analysis using rabbit antibody against 
the mature domain (IB: BDNF) and mouse antibody recognizing the prodomain (IB: proBDNF). Cell lysates were blotted with 
anti-GFP antibody to normalize viral infection (IB: GFP).
Molecular Brain 2009, 2:27 http://www.molecularbrain.com/content/2/1/27that expressed both BDNF and green fluorescent protein
(GFP) [19]. The multiplicity of infection (MOI) was 10
and 1 for Western blotting and immunostaining, respec-
tively [18]. Such precise controls of Sindbis virus infection
did not promote cell death of the neurons [18]. Western
blotting was performed to compare the processing of
these exogenous proteins. In control neurons expressing
BDNFRR, we detected a doublet band of 29- and 32-kDa
(proBDNF) and a 14-kDa band (matBDNF), using either
anti-BDNF or anti-Myc antibodies (RR in Fig. 1C, IB:
BDNF and Myc). Exogenously expressed BDNFRR
appeared to be cleaved in a fashion similar to endogenous
BDNF [20]. Interestingly, the proBDNF bands (29- and
32-kDa) were predominant in neurons expressing
BDNFM, BDNFL, or BDNFML, which showed residual lev-
els of matBDNF (14-kDa) (M, L, and ML in Fig. 1C, IB:
BDNF and Myc). This finding was confirmed using a
quantitative analysis (Fig. 1D). Bands corresponding to
precursor BDNF (Fig. 1C, IB: proBDNF) were also
detected using anti-prodomain monoclonal antibody
[Additional file 1B, mouse]. We ascertained that the
apparent difference in the ratio of proBDNF to matBDNF
between the wild-type and BDNF variants was due to dif-
ferences in proteolytic processing and not to variability in
the efficiency of Sindbis virus infection or BDNF expres-
sion levels, as all samples exhibited similar levels of GFP
expression from the bicistronic vector used in this study
(Fig. 1C). However, the total amount of BDNF {(mat-
BDNF + proBDNF)/GFP} was slightly, yet significantly,
reduced in neurons expressing the mutant BDNF con-
structs (Fig. 1E), which suggests that inhibition of
proBDNF cleavage may affect the overall levels of expres-
sion of BDNF. These results showed that the amino acid
substitutions associated with the SNPs (R125M, R127L,
and R125M/R127L) inhibit the proteolytic cleavage of
proBDNF to matBDNF in CNS neurons.
To examine whether the cleavage resistance affected BDNF
secretion, we expressed the constructs encoding Myc-
tagged BDNFRR, BDNFM, BDNFL, or BDNFML in cultured
cortical neurons using the transfection protocol depicted
in Fig. 1C. Supernatants collected 3 days later were immu-
noprecipitated using an anti-Myc antibody conjugated to
agarose beads. Secreted BDNF isoforms were detected by
Western blot analysis using an anti-mature domain anti-
body that detects both proBDNF and matBDNF (Fig. 1F).
Neurons expressing wild-type BDNF (RR) secreted several
BDNF species: 30- and 32-kDa precursor forms, a 26-kDa
intermediate form, and a 14-kDa mature form (RR in Fig.
1F, IB: BDNF). In contrast, supernatants collected from
neurons expressing the BDNF polymorphic variants (M, L,
and ML) contained predominantly the precursor forms
with negligible, but detectable, levels of matBDNF (M, L,
and ML in Fig. 1F, IB: BDNF). These results were con-
firmed using an anti-prodomain monoclonal antibody
(M, L, and ML in Fig. 1F, IB: proBDNF). These results sug-
gest that the BDNF polymorphic variants markedly
inhibit the conversion of proBDNF to matBDNF, either
intracellularly or extracellularly, and that they are mainly
secreted as proBDNF.
Inhibition of proBDNF cleavage does not affect 
intracellular transportation and secretion of BDNF in 
hippocampal neurons
Previous studies suggest that inhibition of intracellular
cleavage by furin alters the subcellular distribution and
secretion of neurotrophins, particularly of NT-3 [21]. To
determine whether the two SNPs affect the intracellular
distribution of BDNF, we expressed transgenes encoding
GFP-tagged (C-terminus) wild-type BDNF (BDNF-GFP)
or cleavage-resistant R125M/R127L-BDNF (CR-
proBDNF) in cultured hippocampal neurons according to
a previous report [18] (Fig. 2A). The two fusion proteins
exhibited similar distribution patterns in the cell body
and neuronal processes (Fig. 2A, arrows). Immunocyto-
chemical analysis demonstrated that both BDNF-GFP and
CR-proBDNF-GFP colocalized with a trans-Golgi network
marker, TGN38 (Fig. 2B, arrows) and a secretory vesicle
marker, secretogranin II (SgII) (Fig. 2C, arrows). An
immunostaining study further showed that the signals of
BDNF-Myc or CR-proBDNF-Myc were largely colocalized
with the proBDNF signals (Fig. 2D, arrows). These find-
ings, together with the result of Fig. 1F, suggest that inhi-
bition of BDNF cleavage by the amino acid substitutions
did not greatly influence the subcellular distribution of
BDNF and that intracellular cleavage of proBDNF is not a
critical step for intracellular transportation and secretion
of BDNF in hippocampal neurons.
Recombinant CR-proBDNF elicits apoptosis of cerebellar 
granule neurons cultured in low K+ containing medium
To test the biological effects of the CR-proBDNF in vitro,
we purified the recombinant mutant protein using either
the Baculovirus [22] or E. coli expression systems [23]. The
identity of the purified proteins was confirmed using sil-
ver staining via analysis of their comigration with a molec-
ular weight marker (~30-kDa) and detection on Western
blot using a proBDNF-specific antibody (Fig. 3A). Baculo-
viruses expressed two BDNF isoforms that migrated at
approximately 30- and 32-kDa; the latter was likely to be
a glycosylated form (Fig. 3A, left). The CR-proBDNF pro-
tein expressed in E. coli formed inclusion bodies; there-
fore, we used urea denaturation for purification followed
by refolding of the protein. The refolded CR-proBDNF
exhibited a secondary structure, as assessed using circular
dichroism (CD) spectroscopy [Additional file 2A].
To address the role of proBDNF on cell viability of CNS
neurons, we first examined the function of E. coli-derived
CR-proBDNF protein in cultured cerebellar granule neu-Page 4 of 19
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tors [24]. CGNs require high levels of extracellular K+ (HK,
26 mM) for survival. In addition, a low extracellular K+
concentration (LK, 5 mM) induces apoptosis [25]. Cell
viability of CGNs was assessed 48 h later using DAPI stain-
ing, which allows the visualization of apoptosis-induced
chromatin condensation in the nucleus. Consistently with
previous reports [26,27], matBDNF promoted the survival
of CGNs, even when cell death was induced by LK (Fig.
3B, matBDNF, arrows). However, CR-proBDNF failed to
prevent apoptosis induced by LK (Fig. 3B, CR-proBDNF,
arrowheads). Quantitative analysis (Fig. 3C) revealed that
100 ng/ml CR-proBDNF promoted LK-induced apoptosis
in CGNs and increased the number of dying cells by 57.0
± 0.2% when compared with the mock culture (ANOVA
followed by post-hoc analysis; **P < 0.01). In contrast,
100 ng/ml matBDNF significantly inhibited LK-induced
apoptosis in CGNs when compared with the mock culture
(39.0 ± 0.0%, **P < 0.01) [26,27]. These results suggest
that CR-proBDNF promotes LK-induced apoptosis of cul-
tured CGNs and that CR-proBDNF and matBDNF exert
the opposite biological effect on the survival of CGNs.
A previous study demonstrated that recombinant cleav-
age-resistant proBDNF, at subnanomoler concentration,
elicited apoptosis of NGF-deprived superior cervical gan-
glion (SCG) neurons [7]. We therefore investigated the
effect of E. coli-derived CR-proBDNF on apoptosis of LK-
Intracellular proteolytic cleavage of proBDNF is not a crucial step for intracellular transportation and secretion of BDNF in hippocampal neur nsFigur  2
Intracellular proteolytic cleavage of proBDNF is not a crucial step for intracellular transportation and secre-
tion of BDNF in hippocampal neurons. (A) Distribution of GFP-tagged wild-type BDNF (BDNF-GFP) and cleavage-resist-
ant (CR)-proBDNF (R125M/R127L-BDNF-GFP) in the cell body and processes. Cultured neurons were subjected to Sindbis 
viruses expressing the indicated constructs for 3 h. Three days later, the neurons were fixed for imaging of GFP fluorescence 
using confocal microscope. Representative low-magnification (upper) and high-magnification images of the cell body (middle) 
and neuronal processes (bottom) are shown. (B-C) The infected cells were immunostained with the indicated antibodies for 
confocal imaging. Note that CR-proBDNF-GFP greatly co-localized with TGN38 (B) and SgII (C), similarly to wild-type BDNF-
GFP (arrows). Scale bar in all images, 10 μm. (D) Expression of wild-type proBDNF-Myc or CR-proBDNF-Myc. Hippocampal 
neurons were introduced with constructs encoding GFP and wild-type BDNF-Myc or CR-proBDNF-Myc using Sindbis virus 
expression system. Three-days after a brief (3 h) infection, cells were double-stained using anti-Myc and anti-proBDNF anti-
bodies. BDNF-Myc signals largely co-localized with proBDNF signals (arrows) indicating that proBDNF is the predominant 
intracellular isoform. Scale bar, 5 μm.Page 5 of 19
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increase in the number of apoptotic CGN neurons was
found even at 10 ng/ml (0.2 nM) CR-proBDNF, to a sim-
ilar extent to that of 100 ng/ml (Fig. 3D). In addition, E.
coli-derived CR-proBDNF failed to induce TrkB phospho-
rylation for up to 360 min after the application [Addi-
tional file 2B] and CR-proBDNF-induced cell death was
not significantly found in CGNs derived from p75NTR-/-
mice [Additional file 2C, p75NTR-/-, t-test, P = 0.145, com-
pared to Mock]. Finally, a proapoptotic effect was evident
for CR-proBDNF derived from both Baculovirus and E.
coli, whereas heat-denatured CR-proBDNF had no effect
[Additional file 2D]. These results together suggest that E.
coli-derived CR-proBDNF has a proBDNF biological activ-
ity to the similar to mammalian cell-derived proBDNF
[7].
We also examined whether CR-proBDNF could affect the
survival of CGNs cultured in HK medium, which pro-
motes the survival of these cells [25]. Quantitative analy-
sis of cell death using DAPI staining revealed that neither
CR-proBDNF nor matBDNF had a significant effect on the
number of CGNs in this survival-promoting medium
[Additional file 2E], suggesting that proBDNF is proapop-
totic in vulnerable neurons rather than in healthy neurons
and that compared to peripheral neurons CNS neurons
may not be so sensitive to proBDNF. Finally, it is notable
that the BDNF polymorphisms, which lead to an ineffi-
cient cleavage of proBDNF, might be risk factors for
defects in CGNs development and/or survival.
CR-proBDNF inhibits neurite growth in basal forebrain 
cholinergic neurons
To examine whether proBDNF-induced apoptosis is a
general phenomenon in all CNS neurons that express
p75NTR, we chose to use basal forebrain cholinergic neu-
rons (BFCNs), which are known to express high levels of
p75NTR [24]. A large body of evidence demonstrates that
matBDNF promotes survival and differentiation of BFCNs
[1]. A previous, yet initial, report characterized biological
response of the BFCNs to matBDNF [28]: (1) the pro-sur-
vival effect was relatively more striking in low-density cul-
tures, while the differentiated effects were more
pronounced in high-density culture and (2) delayed
application of matBDNF diminished the pro-survival
effect even in low-density culture. In the present study, we
sought to apply CR-proBDNF to rat BF neurons cultured
in serum-containing medium for 2 weeks in order to see
the biological action of proBDNF on BFCNs.
Consistently with previous reports [28,29], 4-day treat-
ment with matBDNF (100 ng/ml) markedly increased the
number and complexity of acetylcholine esterase (AChE)-
positive neurites of the 2-week cultured BFCNs (Fig. 4A
and 4C, matBDNF). The cell viability of the AChE-positive
BFCNs was assessed by DAPI staining (Fig. 4A). Unlike
what was observed in CGNs, neither matBDNF nor CR-
proBDNF (E. Coli-derived recombinant protein) has a sig-
nificant effect on the number of the survived BFCNs and
on the nuclear morphology (Fig. 4A, arrows, and 4B).
However, CR-proBDNF caused the opposite effect on fiber
density in BFCNs: treatment with 100 ng/ml CR-
proBDNF for 4 days led to a marked reduction in the neu-
rite number of AChE-positive neurites extending out-
wards from the cells (Fig. 4D, CR-proBDNF), without
affecting the survival of these cells (Fig. 4C, CR-
proBDNF). Quantitative analysis showed that CR-
proBDNF decreased the number of primary fibers by more
than 45% (Fig. 4D, CR-proBDNF). In contrast, matBDNF
increased the number of the AChE-positive fibers by
approximately 17% (Fig. 4D, mBDNF). We performed
several methods to evaluate of neurite growth. Sholl anal-
ysis, which is used to assess the number and complexity of
fibers extending out from the cell body [30], revealed that
CR-proBDNF significantly reduced the number of cholin-
ergic fibers in the first 10 μm from the cell body by 42%
(Fig. 4E, CR-proBDNF). We also determined the neurite
density of BFCNs in culture dishes (intensity of choliner-
gic fibers/number of cholinergic neurons). The opposing
effects of matBDNF and CR-proBDNF on the fiber density
were confirmed by this quantitative method (see Meth-
ods): Mock 100 ± 13.6% (as control); matBDNF, 149 ±
9.3%**; CR-proBDNF, 37.3 ± 9.4%** (t-test, **P < 0.01,
compared to Mock; n = 6 independent culture dishes)
(Fig. 4F). These results together suggest that CR-proBDNF
inhibits neurite growth of BFCNs while matBDNF
enhances this growth.
Finally, we examined whether CR-proBDNF had the sim-
ilar effect on fiber density of BFCNs in serum-free condi-
tion. To this end, we cultured BFCNs in serum-free
medium containing 5 μg/ml transferrin, 5 μg/ml insulin,
20 nM progesterone and 10 μM cytosine arabinoside
(AraC) [29] for 2 weeks and applied CR-proBDNF to the
neurons in the same medium. Four-day treatment with
CR-proBDNF significantly decreased the fiber density, but
not cell viability, of BFCNs, and even at subnanomoler
concentration the effect of CR-proBDNF was significant
(t-test, **P < 0.01) compared to that of un-treated cultures
(Fig. 4G). These data suggest that proBDNF acts to BFCNs
in a direct manner for negative regulation of the neurite
density.
CR-proBDNF reduces dendritic spine density of 
hippocampal neurons in primary and slice cultures
As proBDNF facilitates LTD [15], proBDNF may have dis-
tinct biological roles in synaptic plasticity [10]. To test this
possibility, we cultured hippocampal neurons (6–8 × 104
cells/cm2) for 3–4 weeks and then applied 50 ng/ml of
matBDNF or proBDNF for 2 days. We first performed DiIPage 6 of 19
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Recombinant CR-proBDNF induces apoptosis of cerebellar granule neurons cultured in low K+-containing mediumFigure 3
Recombinant CR-proBDNF induces apoptosis of cerebellar granule neurons cultured in low K+-containing 
medium. (A) Preparation of recombinant CR-proBDNF (R125M/R127L-BDNF: proBDNFML) using the Baculovirus or E. coli 
expression systems. Protein products were analyzed by silver staining (left) and Western blotting using rabbit antibody against 
BDNF prodomain. (B-C) Opposite actions of CR-proBDNF and matBDNF revealed by apoptosis assay. After 4 days of culture 
in HK medium, CGNs were treated with E. coli-derived CR-proBDNF or matBDNF in LK medium. Cell death was assessed 
using DAPI staining 48 h after treatment with the indicated drug in LK medium. (B) Arrows and arrowheads indicate represent-
ative living and dead cells, respectively. Scale bar, 50 μm. (C) For quantification of cell death, 300–400 cells were counted in 
four independent fields per coverslip. (D) Dose-dependent test of pro-apoptotic activity of CR-proBDNF. Cell death was 
assessed using DAPI staining 48 h after treatment with CR-proBDNF in LK medium. DAPI data were expressed as the percent-
age of mock cultures. In the cell death assay (C-D), n = 4 independent culture dishes. ANOVA followed by post-hoc analysis, 
*P < 0.05; **P < 0.01. Results were replicated in at least three independent experiments.
Molecular Brain 2009, 2:27 http://www.molecularbrain.com/content/2/1/27labeling of dendritic spine structures [31]. Consistently
with a previous report [32], matBDNF dramatically
increased spine density in hippocampal neurons (Fig. 5A,
matBDNF, arrows). However, CR-proBDNF appeared to
promote the density of spine protrusions (Fig. 5A, CR-
proBDNF, arrowheads), which suggests that proBDNF
negatively regulates dendritic spine density in CNS neu-
rons. To evaluate this effect of CR-proBDNF in a quantita-
tive manner, we assessed the density of dendritic spines
with a typical mushroom head and length (> 1 μm) on the
proximal region of dendrites, as described [31,33]. Quan-
titative analysis demonstrated that matBDNF increased
dendritic spine density by 34.9 ± 8.9%, whereas CR-
proBDNF decreased spine density by 41.6 ± 9.0% (Fig. 5A,
left graph, nonparametric test; *P < 0.05 when compared
with Mock). Finally, cultured hippocampal neurons
treated with heat-denatured CR-proBDNF (50 ng/ml, 2
days) had a dendritic spine density that was 77.2 ± 0.1%
higher than that observed with CR-proBDNF (t-test, **P <
0.001, compared to CR-proBDNF-treated cells, n = 41
(CR-proBDNF), 77 (heat-denatured CR-proBDNF) inde-
pendent cells), suggesting that the reduction of dendritic
spine density is a biological activity of proBDNF protein.
We further visualized spine protrusions using the F-actin-
binding dye phalloidin [34]. Similarly to the results
obtained in Fig. 5A, matBDNF and CR-proBDNF had
opposite effects on dendritic spine formation (Fig. 5B,
arrows and arrowheads). Quantitative analysis in a simi-
lar manner to Figure 5A the similar CR-proBDNF
decreased the density of phalloidin-labeled spines by 41.6
± 9.0% (Fig. 5B, right, CR-proBDNF, nonparametric test;
*P < 0.05 when compared with Mock). We further tested
whether a functionally blocking antibody against p75NTR,
AB1554 [35,36] inhibited the effect of CR-proBDNF on
spine density, because it was reported that, after 14 d in
vitro, hippocampal neurons allowed the significant colo-
calization of p75NTR with PSD95 [15]. Treatment with
AB1554 (1/100 dilution) significantly rescued the effect
of CR-proBDNF on spine density (Fig. 5B, right, CR-
proBDNF + AB1554), suggesting that proBDNF involves
p75NTR on the neuronal surface to reduce the spine den-
sity. We next examined the effect of CR-proBDNF (50 ng/
ml, 2 days) on the number of MAP-2-positive neurons in
culture. Quantitative analysis revealed that CR-proBDNF
did not affect the survival nor the overall dendritic mor-
phology of the cultured mature hippocampal neurons
used in this experiment [Additional file 3], suggesting that
this effect of CR-proBDNF on spine density may not be
due to the proapoptotic effect of proBDNF.
Additionally, we examined whether CR-proBDNF affected
spine density in serum-free and low-density cultures of
hippocampal neurons, as described in Methods. In this
culture, the percentage of contaminated glial cells was 7.0
± 1.4% (n = 4 independent culture dishes). Treatment of
CR-proBDNF for 2 days led to a significant decrease in
spine density and 10 ng/ml (0.2 nM) was sufficient for the
negative action of CR-proBDNF (Fig. 5C). These data sup-
port the notion that proBDNF reduces spine density of
hippocampal neurons in a direct manner.
Finally, to evaluate this novel effect of CR-proBDNF in
physiological contexts, we carried out two additional
experiments. First, we investigated the effect of CR-
proBDNF on dendritic spine density in hippocampal slice
cultures. Interestingly, CR-proBDNF (50 ng/ml, 2 days)
reduced the density of spines in hippocampal slice cul-
tures (Fig. 5D, CR-proBDNF). Second, we recorded spon-
taneous miniature excitatory postsynaptic currents
(mEPSCs) [37,38] in cultured hippocampal neurons (21
days in vitro) after 2-day treatment with matBDNF or CR-
proBDNF (50 ng/ml). Hippocampal neurons treated with
CR-proBDNF exhibited basal synaptic transmission (Fig.
6A), which support the notion that CR-proBDNF does not
affect the survival of more than 3 week-cultured hippoc-
ampal neurons [Additional file 3]. However, proBDNF
treatment significantly decreased the amplitude of mEP-
SCs (Fig. 6B, left, nonparametric test, *P < 0.05 when
compared with the Mock group). As reported previously
[39], the amplitude of mEPSCs did not increase signifi-
cantly after matBDNF treatment. Neither matBDNF nor
CR-proBDNF significantly affected the frequency of mEP-
SCs (Fig. 6B, right). These results together suggest that
proBDNF reduces dendritic spine density of CNS neurons
in slice culture and attenuates the amplitude of functional
synaptic transmission.
Discussion
Since the discovery that proNGF binds p75NTR with a
higher affinity than matNGF and that it induces apoptosis
rather than enhancing cell survival in sympathetic neu-
rons [4], proneurotrophin-p75NTR signaling and function
have returned to the center stage in the field of neuro-
trophin research. There is a pressing need to understand
the cleavage of proneurotrophins, as well as their biologi-
cal functions in different brain regions. A crucial, yet
poorly solved, issue is whether proBDNF has a physiolog-
ical function [13]. In the present study, based on a predic-
tive study of BDNF protein variants, we first provided
molecular and cellular insights on the possible conse-
quences that the rare human SNPs have near the cleavage
site of proBDNF (Figs. 1 and 2). Second, we demonstrated
that the poorly cleaved proBDNF (CR-proBDNF)
enhances apoptosis in cultured CGNs (Fig. 3). Finally, we
demonstrated the novel actions of proBDNF, which
include the inhibition of neurite outgrowth in BFCNs
(Fig. 4) and the reduction of dendritic spine density in
mature hippocampal neurons (Fig. 5). These results sug-
gest that proBDNF cleavage is a crucial step for the nega-Page 8 of 19
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Neurite growth of basal forebrain cholinergic neurons is inhibited by CR-proBDNF, but elicited by matBDNFFig re 4
Neurite growth of basal forebrain cholinergic neurons is inhibited by CR-proBDNF, but elicited by matBDNF. 
BFCNs were cultured in serum-containig (A-E) or serum-free (F) medium for 2 weeks and treated with 100 ng/ml CR-
proBDNF or matBDNF in the same medium condition for 2 days. Histochemistry and quantitation of AChE-positve neurites 
were done as described in Methods. (A) BFCNs were double-stained using AChE histochemistry and Hoechst 33258 (arrows). 
(B) The survival rate of BFCNs (%) = 100 × [living cells]/([living cells] + [dead cells]). Data were normalized to mock cultures 
(100% as control). n = 159 (Mock), 151 (matBDNF), and 149 (CR-proBDNF) from three independent coverslips. Results were 
replicated in three independent experiments. (C) Low- and high-magnification images of AChE-stained BFCNs. (D) The 
number of neurites extending outwards from the cell body shown in C. n = 38 (Mock), 37 (matBDNF), and 40 (CR-proBDNF) 
cells from three independent coverslips. (E) Neurite complexity as revealed by Sholl analysis. n = 30 (Mock), 30 (matBDNF), 
and 30 (CR-proBDNF) cells from three independent coverslips. In multi-bar graphs, ANOVA followed by post-hoc analysis 
was used. **P < 0.01. Results were replicated in at least three independent experiments. (F) The opposing effects of matBDNF 
and CR-proBDNF on neurite fiber density were confirmed by a distinct quantitative method. The maximal threshold of AChE-
positive cholinergic fiber intensity was defined as 70% above the background. The total intensity of the fibers was determined 
in an optical field and was divided by the number of AChE-positive neurons in the same field. Data were collected from four 
independent fields in a single chamber. t-test, **P < 0.01, compared to Mock (100% as control); n = 6 independent culture 
dishes. Scale bar, 5 μm (A and C). (G) Effect of CR-proBDNF on neurite density of BFCNs in serum-free condition and a dose-
dependency test of CR-proBDNF. Cell survival (left) and the neurite number of BFCNs (right) were determined. Note that 
proBDNF negatively regulates the neurite density of BFCNs in serum-free conditions and at subnanomoler concentration. n = 
3 independent coverslips. t-test, **P < 0.01, significantly different from Mock.
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that proBDNF exerts multiple biological actions on CNS
neurons.
Although the rare human BDNF polymorphisms studied
here are validated by the National Center for Biotechnol-
ogy Information (NCBI) and the mutations cause amino
acid substitutions near the cleavage site of proBDNF, the
functional and physiological impacts remain ill-defined.
Applying a bioinformatic analysis (PONDR), we pre-
dicted that the mutants would undergo disordered-to-
ordered transitions around the proteinase cleavage site of
proBDNF (Fig. 1B). The inhibition of proteolytic cleavage
of the BDNF polymorphic variants was demonstrated by
Western blot analysis of cultured neurons transfected with
constructs encoding the variant forms of proBDNF (Fig.
1C) and an in vitro protease digestion assay [Additional
file 4]. Interestingly, it was reported that a specific plas-
min-cleavage could occur after Arg125 rather than Arg128
of the RVRR sequence [40]. Nakayama (1997) also
described in a review article that since furin cleavage is
essential for the production of a wide variety of biologi-
cally active proteins it is possible that mutation of the
furin cleavage site of the precursors may result in genetic
disorders [41]. Additionally, we have recently generated a
knock-in mouse line by replacing the endogenous BDNF
allele with a CR-proBDNF-encoding construct and found
inefficient processing of the mutant proBDNF protein
(data not shown), suggesting that the human BDNF poly-
morphisms would cause reduced the conversion of
proBDNF into matBDNF in vivo.
We further demonstrated that the intracellular distribu-
tion (trans-Golgi and secretory granules) and subcellular
localization (dendrites and soma) of CR-proBDNF were
normal (Fig. 2), which suggests that the amino acid sub-
stitutions per se do not alter intracellular sorting and traf-
ficking and supports the notion that endogenous
proBDNF is transported [12] and secreted in an activity-
dependent manner [42]. In this context, these findings are
in marked contrast to those obtained for the Val66Met
variation of BDNF, which leads to the striking alteration
of the sorting of BDNF to the secretory granules and of its
subsequent activity-dependent secretion [18,43].
Two recent reports described the mechanisms of BDNF
secretion [11,12]. In mixed cultures of neurons and glial
cells, proBDNF was rapidly converted into matBDNF and
was secreted as matBDNF. In neuron-rich cultures, how-
ever, proBDNF was the predominant form released. These
two reports suggest that proBDNF cleavage in the nervous
system is regulated in a more specific manner and on cel-
lular context [13]. Although our results stemmed from
overexpression experiments, the inhibition of proBDNF
cleavage significantly reduced the content of BDNF in
cells and resulted in the predominant secretion of the
proBDNF when compared with wild-type BDNF. Our in
silico prediction study suggested that the prodomain was
structurally disordered thus rendering it likely to be degra-
dation (Fig. 1B). Together, these results raise questions
about the roles of the BDNF prodomain and the stable
presence of proBDNF inside and outside of neurons.
Based on studies on proNGF, the concept is emerging that
mature neurotrophins promote cell survival, while prone-
urotrophins facilitate apoptosis [9]. A recent study
showed that proBDNF also promotes the death of sympa-
thetic neurons, which extends the pro-apoptotic role to a
second member of the neurotrophin family [7]; however,
little is known about the inhibitory action of proBDNF on
the survival of CNS neurons [8]. Using primary cultures of
CGNs derived from rat and p75NTR-knockout mice, we
demonstrate that CR-proBDNF enhances LK-induced
apoptosis in CGNs (Fig. 3, [Additional file 2]). It is also
noteworthy that we have developed a simple protocol to
generate recombinant proBDNF from E. coli. (Fig. 3A,
[Additional file 2A]). First, the recombinant proBDNF,
which, even at subnanomolar concentrations, signifi-
cantly promoted apoptosis of cultured CGNs (Fig. 3D),
[Additional file 2]. Second, E. coli-derived CR-proBDNF
failed to induce TrkB phosphorylation for up to 360 min
after the application [Additional file 2B]. Third, similar to
the previous reports [7,8], in the absence of p75NTR, E.
coli-derived CR-proBDNF failed to promote apoptosis of
CGNs [Additional file. 2B]. We also showed that silk-
worm-derived CR-proBDNF is capable of promoting
apoptosis of cultured CGNs. These results are conceptu-
ally parallel to previous reports using recombinant
proBDNF derived from mammalian cells [7,8].
The extent of the opposite actions of proBDNF and mat-
BDNF in the CNS has yet to be determined extensively.
Intriguingly, the present study demonstrated that
proBDNF is capable of reducing the extent of neurite
branching in BFCNs (Fig. 4), which are a well-known pop-
ulation of p75NTR-highly expressing neurons in the adult
brain [24]. However, the morphological action is incon-
sistent with that of a previous report demonstrating that
BF neurons exhibited apoptosis in response to proNGF
and proBDNF in culture [8]. One explanation for such a
discrepancy is that there were likely differences in matura-
tion of the neurons in culture dishes. We applied CR-
proBDNF to BFCNs cultured for more than 2 weeks. A pre-
vious report demonstrated that delayed application of
matBDNF promoted neuronal differentiation rather than
cell survival of the neurons [28]. Since this effect of CR-
proBDNF was observed both in serum-containing and
serum-free medium (Fig. 4G), we have reasoned that
proBDNF may act to the BFCNs in a direct manner.
Another interesting finding was that proBDNF reducedPage 10 of 19
(page number not for citation purposes)
Molecular Brain 2009, 2:27 http://www.molecularbrain.com/content/2/1/27
Page 11 of 19
(page number not for citation purposes)
proBDNF reduces dendritic spine density in hippocampal neuronsFigure 5
proBDNF reduces dendritic spine density in hippocampal neurons. Cultured neurons were maintained for 3–4 weeks 
and treated with the indicated reagents (50 ng/ml) for 2 (A, B, and D) or 3 days (C). In A and B, neurons were cultured in 
serum-containing medium. (A) CR-proBDNF reduced the density of DiI-labeled spines. Representative images of DiI-labeled 
neurons treated with the indicated reagents for 2 days (left). Summary of spine density (middle) and length (right). Data were 
collected from 52 (Mock), 59 (matBDNF), and 38 (CR-proBDNF) independent cells (non-parametric test, *P < 0.05, compared 
to Mock). Note that matBDNF increased spine density, while proBDNF reduced spine density (arrows and arrowheads). (B) 
proBDNF promoted the shrinkage of phalloidin-labeled spines and p75NTR was involved in the proBDNF action. Application of 
a functionally blocking antibody against p75NTR, AB1554 was performed and fixed neurons were stained with an anti-MAP2 
antibody and FITC-labeled phalloidin. Representative images of the double-stained neurons (left) and a quantitative analysis of 
phalloidin-labeled spiny structures (right) are shown, n = 30–40 independent cells from three independent coverslips. t-test, *P 
< 0.05, **P < 0.01, compared to Mock (100% as control). (C) CR-proBDNF decreases spine density in low-density hippocam-
pal neurons cultured in serum-free medium. The cultures were incubated with CR-proBDNF in serum-free medium for 2 days 
and double-stained with an anti-MAP2 antibody and FITC-labeled phalloidin. n = 24–32 cells from three independent coverslips. 
t-test, *P < 0.05, **P < 0.01, compared to Mock. (D) CR-proBDNF decreased spine density in hippocampal slices. Representa-
tive images of DiI-labeled neurons at low and high magnification are shown (left). A decrease in spine density was observed in 
CR-proBDNF-treated slices (arrow heads). Quantification of spine density (right). Data were collected from 7 (Mock) and 6 
(CR-proBDNF) independent slices. Note that CR-proBDNF-treated slices showed a decrease in spine density when compared 
with matBDNF. t-test, *P < 0.05. Scale bar, 10 μm (A, B, and D).
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hippocampal neurons treated with CR-proBDNF exhib-
ited a marked shrinkage of spines, both in dissociated cul-
ture and in slice culture. This new finding leads us to
formulate several important suggestions. First, matBDNF
and proBDNF may play opposite roles in structural plas-
ticity: matBDNF and proBDNF may contribute to the aug-
mentation and elimination of synaptic connections,
respectively (Fig. 5). Second, it was recently demonstrated
that low-frequency stimulation induced predominantly
the secretion of endogenous proBDNF from cultured hip-
pocampal neurons [42]. Short-term exposure of CA1 syn-
apses to proBDNF facilitates LTD [15]. We showed that
CR-proBDNF, which decreased the density of dendritic
spines in hippocampal neurons, also reduced the ampli-
tude of mEPSCs (Fig. 6). In addition to these studies using
dissociated hippocampal neurons on the feeder layer of
glial cells, proBDNF decreased spine density in a low-den-
sity culture and the effect was significant even at subna-
nomolar concentration (Fig. 5C). The treatment with CR-
proBDNF did not affect the number of MAP2-positive
neurons in the culture dishes [Additional file 3]. These
additional data support the notion that proBDNF acts on
spine structures in a direct manner.
However, the mechanism underlying proBDNF-mediated
induction of dendritic spine shrinkage remains unclear.
Immunohistochemical study demonstrated that, after 14
d in vitro, p75NTR immunoreactivity as punctate staining
around the cell body as well as dendrites, with distribu-
tion very similar to that of PSD95 immunoreactivity [15].
Zagrebelsky et al. reported a crucial role of p75NTR on
spine formation by gain-of function and loss-of function
studies [44]. In the present study, the inhibitory action of
CR-proBDNF on spine density was rescued by a p75NTR
functional blocking antibody (Fig. 5B), suggesting that
proBDNF/p75NTR signaling reduces spine density of hip-
pocampal neurons. It was reported that the transport of
the signaling complex that contains the p75NTR receptor
and activated Rap1 plays a role in the effect of myelin-
associated glycoprotein (MAG), which is a well-character-
ized axon growth inhibitor [45]. During LTD, Rap medi-
ates the NMDA-R-dependent removal of synaptic AMPA
receptors [46]. Furthermore, LTD induces the shrinkage of
dendritic spines via the action of cofilin [47]. We also
found that the CR-proBDNF-dependent morphological
change of dendritic spines in cultured hippocampal neu-
rons appeared in 30 min (data not shown). These recent
reports, together with our findings, may provide several
clues for the elucidation of the molecular mechanism
underlying the proBDNF-dependent synaptic depression.
Conclusion
The present study suggested that the function of proBDNF
in the CNS is not limited to apoptosis and consolidation
of LTD [10], and that in a cell type-specific fashion
proBDNF affects dendritic growth, spine growth, and cell
survival of CNS neurons. Very recently, it has been dem-
onstrated that proBDNF eliminated presynaptic terminals
using Xenopus nerve-muscle co-cultures [48]. Hence
proBDNF itself and the proteolytic cleavage of proBDNF
could play important roles in the regulation of BDNF sig-
naling in the architecture of the nervous system.
Methods
Materials
Recombinant human matBDNF was kindly provided by
Sumitomo Pharmaceuticals (Osaka, Japan). NGF was
obtained from mouse submaxillary gland [27]. Recom-
binant human NT-3 protein is from Sigma (St. Louis,
MO). The anti-SgII (secretogranin II) antibody was kindly
provided by Dr. T. Watanabe (Asahikawa Medical Col-
lege, Asahikawa, Japan). The anti-BDNF (N-20) and anti-
c-Myc (9E10) were from Santa Cruz Biotechnology (Santa
Cruz, CA); the anti-GFP antibody was from MBL (Nagoya,
Japan); the anti-phospho-Trk (Y490) was from Cell Sign-
aling (Beverly, MA); anti-MAP2 (microtubule-associated
protein 2) and anti-GFAP (glial fibrillary acidic protein)
antibodies were from Sigma; the anti-TGN38 (trans-Golgi
network 38) and anti-TrkB (TrkBout-specific antibody:
clone 47) antibodies were from BD Biosciences (Dickin-
son, San Jose, CA); the Alexa Fluor-conjugated secondary
antibodies were from Molecular Probes (Eugene, OR).
p75NTR functional blocking antibody (AB1556) was from
Chemicon (Temecula, CA).
Hoechst 33258 (bisbenzimide), glutamate, and phalloi-
din (phalloidin-FITC) were from Sigma; 4',6'-diamidino-
2-phenylindole dihydrochloride (DAPI) and 1,1'-diocta-
decyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate
(DiI) were from Molecular probes; lactate dehydrogenase
(LDH) cytotoxicity test was from Wako (Tokyo, Japan).
Transferrin, insulin, progesterone, cytosine arabinoside
(AraC) and polyethylenimine were purchased from
Sigma.
Wistar ST rats and C57BL/6 mice were from NIPPON SLC
(Hamamatsu, Japan). B6C3F1 mice were from the Charles
River Laboratory (Kanagawa, Japan). The p75NTR knock-
out mice (ngfrtm1Jae) were from The Jackson Laboratory
(Bar Harbor, ME). All animal experiments were strictly in
accord with the protocols approved by the Institutional
Animal Care and Use Committee of the AIST.
Primary cultures of CNS neurons and application of the 
indicated reagents
Primary cultures of dissociated rat and mouse CGNs were
prepared from the cerebella of P9 rats and P6-7 p75NTR-/
- mice, respectively, according to a previous report [27]
with some modifications. Briefly, cells were dissociatedPage 12 of 19
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units/ml, Worthington, Lakewood, NJ) at 37°C and were
then cultured in minimum essential medium (MEM,
Gibco, Carlsbad, CA) that contained 5% fetal bovine
serum (FBS), 5% horse serum, to a final cell density of 5 ×
105 cells/cm2 on polyethyleneimine-coated culture plates.
After culture for 1 day in a humidified CO2 (5%) incuba-
tor, the medium was changed to Minimum Essential
Medium (MEM) that contained 26 mM potassium (HK)
and was supplemented with 5% HS and 20 μM AraC.
After 4 days in culture, cells were placed in serum-free
MEM containing 5.4 mM potassium (LK) or HK-MEM, for
experimentation. In separate cultures of CGNs, the per-
centage of GFAP-positive glial cells was 4.3 ± 0.72% (n =
4 independent culture dishes).
Dissociated BFCN cultures were prepared using E20 rats
(Wistar ST) as described [49,50], with a few modifica-
tions. Briefly, the basal forebrain area containing the sep-
tal nuclei was dissected and digested by papain/DNaseI.
Dissociated neurons were seeded onto polyethylenimine-
coated 8-well chamber slide (Nunc, Rochester, NY). To
maintain the cell survival, serum-containing medium
composed of 5% FBS, 5% heat-inactivated HS, and 90%
Dulbecco's minimum essential medium (DMEM, Invitro-
gen, Carlsbad, CA) was used and cells were cultured to a
final density of 3 × 105cells/cm2 on polyethyleneimine-
coated culture plates. The medium was changed every 7
days. After 14 days in culture, the cells were treated with
the indicated reagents in serum-containing medium,
described above. In this preparation, GFAP-positive glial
cells formed a feeder layer under the neurons (data not
shown). In separate experiments (Fig. 4G), BFCNs were
maintained and treated with the indicated drugs in serum-
free defined medium containing 5 μg/ml transferrin, 5 μg/
ml insulin, 20 nM progesterone and 20 μM AraC [29]. The
medium was changed every 3 days. Then, in sister cul-
tures, the percentage of GFAP-positive glial cells was cal-
culated to be 11.4 ± 2.1% (n = 3 independent culture
dishes).
For quantitative analysis of dendritic spine density, disso-
ciated hippocampal neurons were prepared according to
previous reports [37,51] with some modifications. For the
experiments of Figs. 5A and 5B, hippocampi were dis-
sected from embryonic day 18–20 rats and treated with
0.125% trypsin for 15 min at room temperature. The dis-
sociated neurons were plated on polyethylenimine
(0.01%)-coated glass coverslips (Matsunami, Osaka,
Japan) at a density of 6–8 × 104 cells/cm2. The neurons
were first cultured in DMEM containing 5% FBS and 5%
HS. After 4 d in culture, AraC (2 μM) was added for 24 h
to inhibit proliferation of non-neuronal cells. The neu-
rons were then maintained in DMEM containing 10% HS
for up to 3 weeks. Half of the medium was changed twice
weekly. GFAP-positive glial cells formed a feeder layer
under the neurons (data not shown). In separate experi-
ments (Fig. 5C), dissociated neurons (2 × 104 cells/cm2)
were plated on polyethylenimine (0.01%)-coated plastic
Petri-dishes (Corning Costar, Corning, NY) and co-cul-
tured with confluent glial cells cultured on insert cup but
separated by a microporous membrane filter and co-cul-
tured in a common medium (B27/Neurobasal medium,
Invitrogen) supplemented with 10 μM AraC. The medium
was changed every 3 days. The biological assay of Fig. 5C
was performed for 3–4 week cultured neurons. For immu-
noprecipitation (Fig. 1F), primary cultures of cortical neu-
rons (3 × 105 cells/cm2) were prepared from E20 rats [52].
Three-day cultured cerebral cortical neurons were infected
with wild-type or mutant BDNF-expressing Sindbis
viruses for 12 h and maintained in serum-containing
CR-proBDNF attenuates amplitude of functional synaptic transmission in cult red hippocampal neuronsFigu e 6
CR-proBDNF attenuates amplitude of functional syn-
aptic transmission in cultured hippocampal neurons. 
Cells were cultured as described in Fig. 5A and treated with 
the indicated reagents for 3 days. A patch-clamp technique in 
the whole-cell configuration was used to record mEPSCs 
from pyramidal-shaped neurons and all data were statistically 
evaluated. (A) Representative mEPSCs. (B) Amplitude (left) 
and frequency (right) of mEPSCs. Note that proBDNF signifi-
cantly decreased the amplitude, but not the frequency, of 
mEPSCs. Data were collected from 27–31 independent cells 
(non-parametric test, *P < 0.05, significantly different from 
Mock).Page 13 of 19
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the following immunoprecipitation experiment.
Bioinformatical prediction of proBDNF structure
Predictor Of Naturally Disordered Regions (PONDR)
algorithm (http://www.pondr.com/, Molecular kinetics,
Indianapolis, IN) was carried out according to the report
of Romero et al. [16,53]. The PONDR-based prediction of
unstructured regions was performed using the VL-XT pre-
dictor, which stipulates that a residue value that exceeds a
threshold of 0.5 pinpoints a disordered region.
DNA constructs and Sindbis virus infection
The Sindbis vector pSinEGdsp was generously provided
by Dr. H. Nawa (Niigata University, Niigata, Japan). In
this plasmid, two subgenomic promoters were arranged
in tandem and the recombinant enhanced GFP (EGFP)
gene was subcloned downstream of the second subge-
nomic promoter [19]. The human BDNF cDNA was sub-
cloned into the pBluescript vector (Stratagene, La Jolla,
CA). The Myc epitope tag was added to the 3' end of BDNF
cDNA using a PCR method and the resulting BDNF-Myc
fragment was subcloned into the pCR-Blunt II Topo Vec-
tor (Invitrogen). The variants with substituted Arg to Met
at codon 125 and Arg to Leu at codon 127, as well as the
double substitution (Arg125Met and Arg127Leu), were
generated using the PCR-based Site Directed Mutagenesis
Kit (Stratagene). The integrity of all constructs was con-
firmed by sequencing. For the expression of the EGFP
fusion protein, each DNA fragment was subcloned into
the EGFP-N1 vector (Clontech, Palo Alto, CA) [18]. The
BDNF-Myc constructs and the BDNF-GFP constructs were
subcloned into the Sindbis vectors pSinRep5 (Invitrogen)
and pSinEGdsp, respectively. Sindbis viruses were pro-
duced according to the manufacturer's manual (Invitro-
gen). Sindbis virus infection was performed as described
[18]. The efficiency of the infection was monitored by GFP
fluorescence and the titer used was sufficient for approxi-
mately 100% transduction efficiency for Western blotting
and 10% for immunostaining, respectively.
Recombinant CR-proBDNF produced by the Baculovirus 
expression system
The human cDNA CR-proBDNF (R125M/R127L-BDNF)
was inserted into the Baculovirus transfer vector pYN-
GproBDNFML, which was cotransfected with BmNPV
(CPd strain) DNA into the Bm cell line (BmN) (Katakura
Industries, Saitama, Japan) [22]. Recombinant viruses
were screened using the endpoint dilution method and
were injected into the body cavities of fifth-instar silk-
worm larvae (2 × 106 p.f.u./head). The recovered haemol-
ymph samples were centrifuged at 12,000 × g for 60 min
and the supernatants were stored at -80°C. The mixture
was diluted in Tris solution (10 mM Tris, 10 mM Bis-Tris
Propane, 200 mM NaCl, pH 6.0) and was then loaded
onto an anion exchange column (Poros HQ/1-2312-26,
Applied Biosystems, Foster, CA). After washing the col-
umn with Tris solution, the recombinant proBDNF was
eluted using a linear gradient of NaCl (200 to 1000 mM).
Recombinant proteins were dialyzed in the Tris solution
and stored at 4°C until further use. Purification was mon-
itored by Western blot analysis using an anti-proBDNF
antibody as well as silver staining (Fig. 3).
Recombinant CR-proBDNF produced by the E. coli 
expression system
The His tag was added to CR-proBDNF (R125M/R127L-
BDNF) by PCR; the resulting construct was subcloned into
the pET-19b vector (Novagen, Madison, WI) and was
bidirectionally sequenced. Approximately 6 g of E. Coli
inclusion bodies (IBs)-containing inactive and aggregated
recombinant His-tagged proBDNFML were solubilized
with BugBuster (Novagen). After centrifugation (17,000
rpm, 20 min, 4°C), the IBs were resuspended in Bug-
Buster. This step was repeated 2–3 times. The IBs were sol-
ubilized with 8 M urea solution (8 M urea, 0.5 M Tris-HCl,
pH 8.5, 1 mM EDTA, 40 mM DTT) at 4°C overnight. Deri-
vatization was achieved by adding N- [Tris(hydroxyme-
thyl)methyl]-3-amino propanesulfonic acid (TAPS)-
sulphonate (final concentration, 125 mM; Wako) fol-
lowed by incubation at 4°C overnight. His-tagged CR-
proBDNF was purified using Ni-bead chromatography
(Invitrogen), according to the manufacturer's instructions
and using a 150 mM imidazole solution for elution. For
the refolding of denatured His-tagged CR-proBDNF, dial-
ysis (in 2 M urea, 0.2 mM oxidized cysteamine, 5% glyc-
erol, 50 mM Tris-HCl, pH 7.4) was conducted at 4°C
overnight [23]. For biological assays, the resultant protein
was dialyzed against phosphate-buffered saline (PBS) and
was stored at 4°C until further use. Purification was mon-
itored by Western blot analysis using anti-proBDNF anti-
bodies as well as silver staining (Fig. 3).
Generation of proBDNF-specific antibodies
The entire human prodomain sequence (aa 19–126) of
BDNF was expressed in Rosettagami-2 bacterial cells as a
C-terminal fusion to GST using the pGEX4T-3 vector. The
GST fusion protein was purified using the GST-bind kit,
according to the manufacturer's protocol (Novagen), and
was used to immunize mice and to screen hybridoma
clones. Clone mAb287 was selected from the initial screen
and was further characterized using recombinant proteins
and cell and brain lysates. A polyclonal anti-proBDNF
antibody was raised in rabbits against the recombinant
prodomain (aa 19–126) of the human BDNF (which was
generated in E. coli) conjugated to keyhole limpet hemo-
cyanin (KLH) for immunization. The antibody was affin-
ity-purified against the antigenic protein using the
AminoLink Kit (Pierce Biotechnology, Rockford, IL). A
chick polyclonal anti-proBDNF antibody was raised
against the KLH-conjugated peptide fragment NNKDAD-
LYTSRVMLSSQ, which corresponds to aa 83–99 of thePage 14 of 19
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purified against the antigenic peptide (Aves Labs, Tigard,
OR).
Western blot analyses
The lysates of cultured neurons were prepared as
described [52]. Briefly, cultured cells were rinsed three
times with ice-cold PBS and were quickly lysed in cold
lysis buffer containing 50 mM Tris-HCl (pH 7.4), 1 mM
EDTA, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4, 1%
Triton X-100, 10 mM Na2P2O7, 100 μM phenylarsine
oxide, and 1% protease inhibitor cocktail (Complete
Mini, Roche Diagnostics, Hertforshire, UK). Lysates were
boiled for 5 min at 100°C and were then sonicated. The
protein concentration of the supernatants was determined
using the bovine serum albumine (BSA) standards from
Pierce Biotechnology. The lysates were resolved by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). Western
blot protocols were according to Suzuki et al. (2004) [52]
but modified for detecting signals more specifically. Sam-
ples were sonicated in an equal volume of SDS sample
buffer (0.125 M Tris-HCl, pH 6.8, 20% glycerol, 4% SDS,
and 10% 2-mercaptoethanol), heated at 100°C for 3 min,
and resolved by SDS-PAGE. Samples were electrotrans-
ferred to polyvinylidene fluoride membranes (Immo-
bilon P membrane, Millipore, Bedford, MA), which were
blocked in Tris-buffered saline (TBS) containing 0.2%
Tween-20 (TBS-T) and 3–5% BSA or Block Ace (Dainip-
pon pharmaceutical, Osaka, Japan) and were then incu-
bated with the indicated primary antibodies in TBS-T
containing 0.3–0.5% BSA (TBS-TB) or 1–10% Block Ace
at room temperature for 60–90 min. After washing 3
times with TBS-T, membranes were incubated with perox-
idase-conjugated secondary antibodies in TBS-TB at room
temperature for 30 min, and then washed 3 times with
TBS-T. The chemical luminescence signals were detected
using the ImmunoStar Reagents (Wako) or the SuperSig-
nal West Femto Maximum Sensitivity Substrate (Pierce
Biotechnology). The exposure time was adjusted so that
the intensities of the bands were within the linear range.
For quantification of the relative amounts of proBDNF
and matBDNF, the blots were scanned and the images
were converted to Tiff files and quantified using the NIH
Image software (ImageJ version 1.37v). The relative
amounts of proBDNF and matBDNF were obtained by
normalizing the values to total BDNF values. Signals for
proBDNF and matBDNF in a given lane of the blot (after
subtraction of the background in the same lane) were
added to obtain the value for total BDNF and were nor-
malized to the signal of the GFP band. The data were aver-
aged and were presented as mean ± standard error of the
mean (SEM).
Immunoprecipitation
Protein G Sepharose (15 μl gel, Amersham Pharmacia,
Piscataway, NJ) was added to the conditioned culture
medium of the dissociated cerebral cortical neurons trans-
duced with Myc-tagged CR-proBDNF (R125M/R127L-
BDNF) constructs and the mixture was rotated at 4°C for
60 min. Anti-c-Myc monoclonal antibody-conjugated
agarose beads (20 μl gel, BD, San Jose, CA) were added to
the supernatant after removal of the Protein G Sepharose.
Incubation of the lysates with the beads was performed at
4°C overnight. The immune complexes were pelleted and
immunoblotted using antibodies against BDNF or
proBDNF.
Cell viability assay
Cell viability was quantified by counting the number of
dead cells using DAPI or Hoechst staining [54], and by
measuring LDH released into the medium using the kit
(Wako) [27]. For the LDH assay, culture media were cen-
trifuged at 10,000 g for 10 min and 50 μl of dye buffer
were added to 10–20 μl of each supernatant. The mixtures
were incubated at 37°C for 15 min and 50 μl of terminat-
ing buffer was added to each sample. The absorbance was
photometrically determined at a wavelength of 560 nm.
For DAPI and Hoechst staining, cells were fixed using 4%
paraformaldehyde/PBS for 20 min and were then stained
with 100 ng/ml DAPI or 1 μg/ml Hoechst 33258 in PBS
for 15 min. The ratio of condensed to intact nuclei was
quantified based on observations using a fluorescence
microscope.
AChE histochemistry and quantitative analysis
Fixation and immunohistochemistry of cultured choliner-
gic neurons were performed according to previously
described methods [49,50]. AChE histochemistry was per-
formed as described [55]. The phase-contrast images of
AChE-positive cholinergic fibers and the cell body with a
diameter of > 2.5 μm were acquired using a cooled CCD
camera (MRc5, Carl Zeiss, Swiss) mounted on a Nikon
microscope (TE230, Nikon, Japan). Sholl analysis was
performed to determine the number of AChE-positive
neurites at a distance of 10 μm from the soma [30]. The
number of AChE-positive cholinergic fibers that extended
from the cell body were counted according to Suzuki et al.
(2004) [52]. We also quantified cholinergic fiber density
using the following method: images of AChE-positive
cholinergic fibers were captured using the optical condi-
tions described above. First, the background intensity was
determined by averaging the values obtained from three
non-stained areas. The maximal threshold of fiber inten-
sity was defined as 70% above the background intensity.
The total intensity of the AChE-positive fibers was deter-
mined in an optical field (500 × 500 pixels/field) and was
divided by the number of AchE-positive cholinergic neu-
rons in the same field. Data were collected from four inde-
pendent fields in a single chamber. All experiments were
performed in a blind fashion.Page 15 of 19
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Dendritic spine density was quantified according to previ-
ous reports [31,33,56], with a few modifications. Cul-
tured hippocampal neurons were treated with the
indicated reagents for 2–3 days and were then fixed using
4% paraformaldehyde/PBS for 20 min. DiI solution (20
mg/ml) was used for labeling dendritic spines. For visual-
ization of F-actin accumulated in the dendritic spines,
fixed cells were immunostained with an anti-MAP2 anti-
body [52], followed by 1 h incubation with TRITC-conju-
gated phalloidin (1:750 in PBS). We used confocal
microscopy (FV-1000, Olympus, Tokyo, Japan) with a 60
× objective lens to capture stacked images of dendritic
spines along the z-axis of the imaged cell. The spatial res-
olution of captured images was 0.1 μm/pixel. The number
of spines was quantitatively evaluated at the proximal side
of the second dendrite via manual counting using Meta-
morph software (Universal Imaging, Downingtown, PA).
Dendritic spines in slice cultures were labeled by rhodam-
ine-dextran injection (6 mg/ml in a patch pipette) using a
single-cell electroporator [57].
Hippocampal slice cultures
Hippocampal organotypic slice cultures were prepared
from B6C3F1 mice (postnatal day 5–7), according to pre-
vious reports [58,59], with a few modifications. Briefly,
hippocampi were dissected in ice-cold choline-based arti-
ficial cerebrospinal fluid (ACSF) (in which NaCl was
replaced by Choline-Cl) and were cut transversely into
350 μm-thick slices. The slices were transferred to Millicall
CM membrane inserts (Millipore) and were maintained
in medium containing 80% modified MEM (described
next) with 20% HS. Modified MEM contained 50% MEM,
25% Hanks' Balanced Salt Solution (HBSS), glucose (30.5
mM), CaCl2 (1 mM), MgCl2 (2 mM), NaHCO3 (13 mM),
ascorbic acid (0.68 mM), and HEPES (25 mM). The cul-
ture medium was half-replaced every 2 days.
Electrophysiology
The electrophysiological study was carried out as
described previously [37,38]. Miniature excitatory synap-
tic currents (mEPSCs) were recordered in the voltage-
clamp mode of the whole-cell patch-clamp technique at
room temperature (23–24°C). The recording chamber
was continuously perfused at a rate of 0.2 ml/min with an
extracellular solution containing 124 mM NaCl, 1.25 mM
NaHPO4, 5 mM KCl, 33.3 mM glucose, 2 mM CaCl2, 1
mM MgCl2, 0.1 mM picrotoxin (PTX) (TCI, Tokyo,
Japan), 0.5 μM tetorodotoxin (TTX), and 22 mM HEPES,
with pH and osmolality adjusted to 7.4 and 310–320
mOsmol with NaOH and sucrose, respectively. The solu-
tions in the patch pipettes contained (in mM) 110 Cs
methanesulfonate, 20 CsCl2, 20 HEPES, 0.1 spermine, 10
Na-phosphocreatine, 0.6 EGTA-Cs, 0.1 GTP-Na3, and 4
ATP-Na2 (pH 7.3). All chemicals used in the electrophysi-
ological experiments were obtained from Wako, unless
otherwise specified. mEPSCs were analyzed using the
MINI ANALYSIS software (Synaptosoft, Decatur, GA) and
house-made macro programs.
Statistical analyses
Typically, significance was determined using the Student's
t-test after testing for normal distribution. In several
multi-bar figures, significance was analyzed by ANOVA
followed by a post-hoc comparison. In all graphs, data
were presented as means ± standard error of the mean
(SEM).
Methods for additional files
Fluorescent cleavage assay
Peptides were prepared in an automated peptide synthe-
sizer (PSSM-8, Shimazu, Japan) using Fmoc chemistry. A
fluorogenic group (7-methoxycoumarin-4-yl acetyl,
MOCAc) and a quenching group (2,4-dinitrophenyl,
DNP) were introduced into peptides using (7-methoxy-
coumarin-4-yl)-acetic acid (Bachem, Bubendorf, Switzer-
land) and N-alpha-fluorenylmethoxycarbonyl-N-epsilon-
dinitrophenyl-lysine (Novabiochem, Laufelfingen, Swit-
zerland), respectively [60]. MOCAc- and DNP-conjugated
peptides (5 mM) were solved in a buffer containing 0.1%
(w/v) Triton X-100, 100 mM HEPES (pH 7.5), and 1 mM
CaCl2. Furin (10 units/ml; Sigma) was added to the pep-
tide solution and the mixture was incubated at 30°C. The
furin digestion was monitored by measuring the fluores-
cence of the cleaved MOCAc-containing peptide at 393
nm after excitation at 323 nm, using an F-4500 Fluores-
cence Spectrophotometer (Hitachi, Tokyo, Japan).
Circular dichroism (CD) measurements
CD measurements were carried out using a spectropola-
rimeter (model J-820, Jasco, Tokyo, Japan). The spectra
were accumulated by performing four scans at a scan rate
of 20 nm/min using a time constant of 1.0 sec. CD spectra
were recorded at 25°C using a cell with a 1 mm path
length. The protein concentration used for all measure-
ments was 21 μM. The concentration of protein samples
was estimated using the calculated molar absorption coef-
ficient at 280 nm (ε280 = 32,275 mol-1cm-1l). The produc-
tion of proNGF and proNT-3 proteins was carried out as
described for CR-proBDNF. Heat-denatured (boiled) CR-
proBDNF was prepared by 30 min boiling prior to the
application to culture dishes.
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Additional file 1
DNA constructs and proBDNF-specific antibodies were generated for 
characterization of R125M, R127, and R125/R127 substitutions. (A) 
DNA constructs used in the present study (Figs. 1 and 2). The DNA con-
structs encoded wild-type, single-, and double-mutant BDNF proteins 
(RR, M, L, ML). The gray, pink, and blue regions indicate the signal pep-
tide, the prodomain, and the mature domain, respectively. The amino acid 
substitutions caused by the SNPs are depicted by white symbols. (B) Spe-
cificity of the proBDNF antibodies. Mouse, rabbit, and chicken antibodies 
specifically recognized E. coli-derived CR-proBDNF (R125M/R127L-
BDNF) on Western blot (Figs. 1 and 3), but not proNGF or proNT-3. 
Ten ng of each recombinant protein was loaded for silver staining and 
immunoblotting. These antibodies did not recognize matBDNF, matNGF, 
or matNT-3 (data not shown).




E. coli-derived CR-proBDNF acquires its proper secondary structure 
and is not able to elicit apoptosis of CGNs cultured in HK medium. 
(A) circular dichroism (CD) spectroscopy of refolded E. coli-derived CR-
proBDNF. The CR-proBDNF (proBDNFML) protein expressed in E. coli 
(Fig. 3A) formed inclusion bodies; therefore, we used urea denaturation 
for purification followed by refolding of the protein (Methods). The 
refolded CR-proBDNF exhibited a secondary structure, as assessed using 
CD spectroscopy. A wavelength scan was acquired from 255–205 nm, 
before (dashed line) and after (solid line) the refolding reaction. The CD 
spectrum demonstrates that the resulting proBDNF had a secondary struc-
ture with a peak at 218 nm. (B-C) CR-proBDNF is not able to activate 
TrkB receptor but involves p75NTR for the cell death. After 4 days of culture 
in HK medium, rat (B) and mouse CGNs (C) were treated with the indi-
cated drug in LK medium. (B) Failure to activate TrkB by CR-proBDNF. 
A time-course study demonstrated that matBDNF, but not CR-proBDNF, 
activated TrkB (upper panel). Western blots were performed with anti-
TrkB (clone 47, BD Biosciences) and anti-phospho-TrkB (Y490, Cell Sig-
naling) antibodies. (C) The proapoptotic effect of CR-proBDNF is 
dependent on p75NTR. CGNs derived from p75NTR-/- mice were processed 
for DAPI staining as described in Fig. 3B. The Student's t-test was used 
and compared to Mock. **P < 0.01. n = 4 independent culture dishes. 
Results were replicated in at least three independent experiments. Please 
note that CR-proBDNF did not significantly induce apoptosis in CGNs 
derived from p75NTR-/- mice. (D) Apoptotic effect of recombinant CR-
proBDNF derived from Baculovirus and E. Coli. CGNs were cultured, 
treated with CR-proBDNF, and apoptosis was measured using the LDH-
cytotoxic assay, as described in Methods. Heat-denatured CR-proBDNF 
was used as a control. In multi-bar graphs, ANOVA was followed by post-
hoc analysis. **P < 0.01, n = 3 independent coverslips. (E) Absence of a 
significant effect of CR-proBDNF on the viability of CGNs cultured in HK 
medium. After 4 days of culture in HK medium, CGNs were treated with 
E. coli-derived CR-proBDNF or matBDNF in HK medium (but not LK 
medium). Cell viability was assessed using the DAPI staining method 48 
h later. n = 3 independent coverslips.




Two-day treatment with proBDNFML does not affect the number of 
MAP2-positive neurons. As described in Fig. 6A, the hippocampal cul-
tures (1 × 105 cells/cm2) were maintained for 3–4 weeks and treated with 
100 ng/ml E. coli-derived CR-proBDNF or 100 ng/ml matBDNF for two 
days. Cells were then fixed and stained using an antibody against MAP2 
[52]. The number of MAP2-positive neurons was counted as described. 
(A) Representative images of MAP2-positive neurons. Scale bar, 10 μm. 
(B) Quantitative analysis of the number of MAP2-positive cells. n = 4 
independent culture dishes. Two-day treatment with matBDNF or CR-
proBDNF did not appear to affect the overall morphology of mature hip-
pocampal neurons.




M, L, and ML variants are resistant to furin, revealed by an in vitro 
protease digestion assay. Ten-amino-acid polypeptides that contained the 
cleavage site of proBDNF with the indicated amino acid residues were 
conjugated with MOCAc and DNP at the N- and C-termini, respectively 
[60]: the latter quenches the fluorescence in the absence of peptide cleav-
age. The peptides were incubated with the widely distributed prohormone 
convertase, furin (10 units/ml) [2]. Cleavage of wild-type BDNF (BDN-
FRR) peptide by furin would separate the fluorogenic group from the 
quencher and would thus generate a measurable fluorescent signal. A 
time-course study revealed a gradual increase in fluorescence after the 
incubation of the BDNFRR peptide with furin [2], which reached a max-
imum at 4 h (black circles). In contrast, R125M-BDNF (BDNFM), 
R127L-BDNF (BDNFL), and R125M/R127L-BDNF (BDNFML) pep-
tides did not elicit a significant increase in fluorescence (red, blue, and 
purple circles, respectively). Mass spectrometric analysis confirmed that 
the BDNFRR peptide was precisely cleaved at the processing site (data not 
shown).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
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